Tradegate
23.12.25 | 17:19
3,500 Euro
+0,29 % +0,010
1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 3,425 | 3,535 | 23.12. | |
| 3,440 | 3,540 | 23.12. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 17.12. | ABIONYX Pharma Carries Out a Capital Increase With Cancellation of Preferential Subscription Rights in Favor of Certain Categories of Persons, Amounting to Approximately €1.8m | 268 | Business Wire | Capital increase of approximately 1.8 million euros Subscription price: 3.10 euros Extension of financial visibility until the end of 2026
Regulatory News:
ABIONYX Pharma, (FR0012616852... ► Artikel lesen | |
| 16.12. | ABIONYX Pharma Is Launching a Capital Increase With Cancellation of Preferential Subscription Rights in Favor of Certain Categories of Persons, Amounting to Approximately €1.8m | 293 | Business Wire | Capital increase of approximately 1.8 million euros Subscription price: 3.10 euros Extension of visibility until the end of 2026
Regulatory News:
ABIONYX Pharma, (FR0012616852... ► Artikel lesen | |
| 05.12. | ABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company's Share Capital | 282 | Business Wire | Article L233-8-II of the French Commercial Code
Article 223-16 of the General Regulations of the AMF (French Financial Markets Authority)
Regulatory News:
ABIONYX Pharma (Paris:ABNX):
Market:... ► Artikel lesen | |
| 25.11. | ABIONYX Pharma Reports on Its Business and Cash Position for the Third Quarter of 2025 | 386 | Business Wire | Consolidated revenue of €3.06 million at the end of September 2025 Cash position of €2.8 million as of September 30, 2025
Regulatory News:
ABIONYX PharmaFR0012616852 ABNX PEA PME... ► Artikel lesen | |
| 20.11. | ABIONYX Pharma and SEBIA form partnership for sepsis diagnostics | 2 | Investing.com | ||
| ABIONYX PHARMA Aktie jetzt für 0€ handeln | |||||
| 20.11. | ABIONYX Pharma and SEBIA Announce an Exclusive Global Strategic Partnership to Transform Sepsis Diagnosis | 299 | Business Wire | Regulatory News:
ABIONYX Pharma, (FR0012616852 ABNX eligible PEA PME), a next-generation biopharma company pioneering a new therapeutic era in sepsis and critical care through its proprietary... ► Artikel lesen | |
| 12.11. | ABIONYX Enters Strategic Discussions With IHU SEPSIS To Redefine Sepsis Treatment Landscape | 1 | RTTNews | ||
| 12.11. | ABIONYX Pharma Enters Advanced Strategic Discussions with IHU SEPSIS, the World's First Center Dedicated to Sepsis | 308 | Business Wire | Transformative alliance to Create the world-leading clinical infrastructure and breakthrough biotechnology to redefine the therapeutic landscape of sepsis.
ABIONYX Pharma, (FR0012616852 ABNX),... ► Artikel lesen | |
| 12.11. | ABIONYX Pharma Announces Advanced Strategic Discussions with IHU SEPSIS, the World's Leading Center Dedicated to Sepsis | 326 | Business Wire | A Transformative and Structuring Alliance for the Global Management of Sepsis
Regulatory News:
ABIONYX Pharma, (FR0012616852 ABNX PEA PME eligible), a next-generation biopharma company pioneering... ► Artikel lesen | |
| 04.11. | ABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company's Share Capital | 247 | Business Wire | Article L233-8-II of the French Commercial Code
Article 223-16 of the General Regulations of the AMF (French Financial Markets Authority)
Regulatory News:
ABIONYX Pharma (Paris:ABNX):
Market:... ► Artikel lesen | |
| 21.10. | ABIONYX Pharma Announces Landmark Validation: A Study Published in NATURE Confirms Genetic Causality of Apolipoprotein A-I (ApoA-I) in Sepsis | 426 | Business Wire | A Global Turning Point for Critical Care Medicine
Regulatory News:
ABIONYX Pharma, (FR0012616852 ABNX PEA PME eligible), a new generation biotech company dedicated to the discovery and development... ► Artikel lesen | |
| 03.10. | ABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company's Share Capital | 357 | Business Wire | Article L233-8-II of the French Commercial Code Article 223-16 of the General Regulations of the AMF (French Financial Markets Authority)
Regulatory News:
ABIONYX Pharma: (Paris:ABNX)
Market:... ► Artikel lesen | |
| 25.09. | ABIONYX Pharma: 2025 Half-Year Financial Results | 404 | Business Wire | Regulatory News:
ABIONYX Pharma, (FR0012616852 ABNX PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies based on the world's... ► Artikel lesen | |
| 05.09. | ABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company's Share Capital | 364 | Business Wire | Article L233-8-II of the French Commercial Code
Article 223-16 of the General Regulations of the AMF (French Financial Markets Authority)
Regulatory News:
ABIONYX Pharma (Paris:ABNX):
Market:... ► Artikel lesen | |
| 28.08. | ABIONYX Pharma Provides an Update on Its Activity and Cash Position for the 2nd Quarter 2025 | 553 | Business Wire | Regulatory News:
ABIONYX Pharma (FR0012616852 ABNX PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies based on the world's... ► Artikel lesen | |
| 27.08. | ABIONYX Pharma Announces the Start of Discussions With a Major Player in the Field of Sepsis for a Strategic Partnership | 685 | Business Wire | Regulatory News:
ABIONYX Pharma (FR0012616852 ABNX PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies based on the world's... ► Artikel lesen | |
| 21.08. | ABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company's Share Capital | 392 | Business Wire | Article L233-8-II of the French Commercial Code Article 223-16 of the General Regulations of the AMF (French Financial Markets Authority)
Regulatory News:
ABIONYX Pharma (Paris:ABNX)
Market:... ► Artikel lesen | |
| 04.07. | ABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company's Share Capital | 482 | Business Wire | Article L233-8-II of the French Commercial Code Article 223-16 of the General Regulations of the AMF (French Financial Markets Authority)
Regulatory News:
ABIONYX Pharma (Paris:ABNX)
Market:... ► Artikel lesen | |
| 03.07. | ABIONYX Pharma: Half-Yearly Report on the Liquidity Contract With TP ICAP (Europe) SA | 479 | Business Wire | Regulatory News:
Under the liquidity contract entered into by ABIONYX Pharma (Paris:ABNX) with TP ICAP (Europe) SA, the following assets were included in the liquidity account at June 30, 2025:... ► Artikel lesen | |
| 27.06. | ABIONYX Pharma Announces Approval of All Resolutions Put to the Vote at Its Combined General Meeting | 433 | Business Wire | Regulatory News:
ABIONYX Pharma, (FR0012616852 ABNX PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies based on the world's... ► Artikel lesen |
1 2 Weiter >>
35 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 79,85 | 0,00 % | BioNTech im Fallen | BioNTech bleibt zuletzt deutlich unter Druck. Der Blick richtet sich auf zentrale Unterstützungen und mögliche Stabilisierungssignale Den vollständigen Artikel lesen ... ► Artikel lesen | |
| EVOTEC | 5,388 | +3,10 % | Revolutionäre Fortschritte: BioTech-Ideen für 2026! Bayer, Novo Nordisk, BioNxt, Vidac, BioNTech und Evotec! | Trotz eines schwierigen Umfelds 2025 bleibt der Biotech-Sektor fundamental attraktiv, da der medizinische Fortschritt nicht zum Stillstand kommt. Der rasante Einsatz von Künstlicher Intelligenz und... ► Artikel lesen | |
| BB BIOTECH | 48,950 | -1,11 % | BB Biotech im Aufwind - Zinswende treibt Biotech-Rally an | US-Zinssenkung belebt den Biotech-Sektor. BB Biotech glänzt mit starkem Quartal, vier Exits und klarer Outperformance gegenüber dem Nasdaq Biotech Index. Seit der ersten Zinssenkung der US-Notenbank... ► Artikel lesen | |
| MEDIGENE | 0,023 | -12,03 % | MEDIGENE AG stürzt ab - das ist erst der Anfang! | ||
| QIAGEN | 38,985 | -0,35 % | QIAGEN N.V.: QIAGEN Announces Details for Completion of Synthetic Share Repurchase of up to Approximately $500 Million | Return of approximately $500 million maximum approved by shareholders set to be completed on January 7, 2026 Capital return to be conducted through synthetic share repurchase combines a... ► Artikel lesen | |
| CUREVAC | 3,536 | +4,12 % | Curevac-Übernahme durch Biontech wird im Januar vollendet | MAINZ/TÜBINGEN (dpa-AFX) - Nach Ablauf einer weiteren Frist soll die Übernahme des Biotechnologieunternehmens Curevac durch Biontech im Januar komplett abgeschlossen werden. Zum Ende einer Nachangebotsfrist... ► Artikel lesen | |
| MODERNA | 27,250 | -0,51 % | Moderna, Inc.: CEPI to Fund Pivotal Phase 3 Trial for Moderna's mRNA Pandemic Influenza Vaccine Candidate | Up to $54.3 million CEPI investment aims to help advance Moderna's H5 pandemic influenza vaccine candidate to licensurePartnership strengthens global preparedness against a significant pandemic threatIf... ► Artikel lesen | |
| VALNEVA | 3,632 | +0,22 % | Abend-Update: Valneva legt kräftig zu - jetzt reden alle über diesen Wert! | ||
| AMGEN | 280,45 | -0,23 % | ROUNDUP/Aktien New York Schluss: Erholung geht weiter | NEW YORK (dpa-AFX) - Die US-Börsen haben sich am Freitag weiter von ihrem jüngsten Rücksetzer erholt. Eine Jahresendrally sei nach wie vor möglich, sagte ein Investmentexperte. Es herrschte unvermindert... ► Artikel lesen | |
| EPIGENOMICS | 0,888 | -0,22 % | PTA-AFR: Epigenomics AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114-117 WpHG | DJ PTA-AFR: Epigenomics AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114-117 WpHG
Vorabbekanntmachung Finanzberichte gemäß ---- 114-117 WpHG
Epigenomics... ► Artikel lesen | |
| NOVAVAX | 5,750 | -0,40 % | Novavax, Inc.: Novavax Reports Third Quarter 2025 Financial Results and Operational Highlights | Total revenue of $70 million in the third quarter of 2025
Continued successful execution of Sanofi partnership with $225 million in milestones achieved year-to-date... ► Artikel lesen | |
| STRYKER | 301,90 | -0,33 % | Intuitive Surgical vs. Stryker: Which MedTech Stock Has More Upside? | ||
| BIOGEN | 147,90 | -0,27 % | Biogen Inc.: The Journal of the American Medical Association (JAMA) Neurology Publishes Long Term Results from the QALSODY Phase 3 VALOR Study and its Open-Label Extension in SOD1-ALS | Long-term data published in JAMA Neurology further illustrate the effects of Biogen's QALSODY on function, strength, and survival in SOD1-ALSOver 3 years, a subset of QALSODY-treated participants regained... ► Artikel lesen | |
| BIOFRONTERA | 2,480 | +4,20 % | PTA-news: Biofrontera AG: Biofrontera berichtet über die Ergebnisse der ersten neun Monate des Jahres 2025 | DJ PTA-News: Biofrontera AG: BIOFRONTERA BERICHTET ÜBER DIE ERGEBNISSE DER ERSTEN NEUN MONATE DES JAHRES 2025
Unternehmensmitteilung für den Kapitalmarkt
Biofrontera AG: BIOFRONTERA... ► Artikel lesen | |
| HEIDELBERG PHARMA | 2,440 | +2,09 % | HEIDELBERG PHARMA AG stürzt ab - ich sehe Rot! |
ABIONYX PHARMA SA gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +0,29 % bei einem Aktienkurs von 3,500 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ABIONYX PHARMA SA finden Sie auf Wallstreet Online.